Citations

Clear

3138 citation(s) found for "Smith, AM".

Steroidogenesis in patients with adrenal incidentalomas: Extended steroid profile measured by liquid chromatography‐mass spectrometry after ACTH stimulation and dexamethasone suppression
Huayllas, Martha Katherine Paniagua , Gallagher, John C. , Netzel, Brian C., Kater, Cláudio E. , Huayllas, Martha K P , Smith, Lynette M. , Singh, Ravinder J.

Mayo Clinic

Clinical Endocrinology | February 18, 2021 | Volume: 95 | Issue: 1 | Pages: 29-40

10.1111/cen.14445 | PMID 33598999 Get It

AbstractObjectiveDescribe the secretion and profile of adrenal steroids in patients with adrenal incidentalomas compared to control subjects.Design, Setting and ParticipantsA prospective study, 73 patients with adrenal incidentalomas, 21 bilateral and 52 unilateral and 34 matched controls in University Hospital.MethodsCollect fasting blood sample before and 60 min after ACTH test (250 µg IV). One week later, perform overnight 1 mg dexamethasone test. The following steroids were measured by liquid chromatography‐mass spectrometry (LC‐MS): pregnenolone, 17‐OH pregnenolone, 17‐OH progesterone, 11‐deoxycorticosterone, 11‐deoxyortisol, 21‐deoxycortisol, corticosterone, cortisol, androstenedione and aldosterone.ResultsMean baseline serum cortisol was higher in incidentalomas, bilateral 361 ± 124, (range 143–665) nmol/L,(p < .0001), unilateral 268 ± 89 3.2 (range 98–507) nmol/L (p < .019) compared to controls 207 ± 100 (range 72–502) nmol/L. ACTH stimulation showed significantly higher levels in bilateral and unilateral cases compared to controls. After dexamethasone, mean serum cortisol levels suppressed in bilaterals 89 ± 69 (range 30–3) nmol/L (p < .0001), 58 ± 52 (range 16–323) nmol/L in unilateral (p < .01) compared to 26 ± 9 (range 7–46) nmol/L in controls. Mean baseline serum corticosterone was higher in bilateral 9.3 ± 4.8 (range 2.4–18.4) nmol/L (p < .005) and unilateral 7.3 ± 5.7 (range 0.1–30.3) nmol/L (p < .01) compared to controls 4.2 ± 2.4 (range 1.1–10.2) nmol/L, after ACTH stimulation significantly increased to higher levels in bilateral (p < .0002) and unilateral cases (p < .044) compared to controls. After dexamethasone, mean levels were 2.5 ± 2.6 (range 0.5–12.5) nmol/L in bilateral (p < .0006), 1.5 ± 1.6 (range 0.3–9.3) nmol/L in unilateral (p < .09) and 0.75 ± 0.46 (range 0.1–2.1) nmol/L in controls. Mean baseline serum 11‐deoxycorticosterone (DOC) was higher in bilaterals 0.32 ± 0.23 (range 0.08–1.1) nmol/L (p < .03) compared to controls 0.15 ± 0.21 (range 0.08–1.1) nmol/L. ACTH stimulation increased levels to 3.27 ± 1.72 (range 0.5–7.4) nmol/L in bilateral cases compared to controls 1.369 ± 1.53 (range 0.1–7.1) nmol/L (p < .0001). Dexamethasone decreased levels to baseline (p ns). There were significant differences in serum 21‐deoxycortisol (p < .0002) and serum pregnenolone (p < .004) only after ACTH stimulation.ConclusionsThere is increased activity in several steroid biosynthesis pathways and higher steroid levels in bilateral compared to unilateral cases and evidence of hypercortisolism in 30% unilateral and 62% of bilateral incidentalomas.
Abstract PS7-49: Assessment of patient out-of-pocket cost for palbociclib therapy in advanced breast cancer
Golbach, Allison P. , Taraba, Jodi L. , Smith, Matthew D. , Taraba, Jodi L , Giridhar, Karthik V.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PS7-49-PS7-49

10.1158/1538-7445.sabcs20-ps7-49 Get It

Abstract Assessment of patient out-of-pocket cost for palbociclib therapy in advanced breast cancerBackground:Palbociclib has demonstrated improved outcomes in patients with advanced hormone receptor positive (HR+)/human epidermal growth factor 2 (HER2) negative breast cancer when used in combination with endocrine therapy 1,2. The current average wholesale price of therapy with this medication class exceeds $190,000 per year (at full dose). Financial toxicity is a major concern in the oncology population and can decrease patient quality of life and may result in non-adherence 3,4. Our objective was to describe the out-of-pocket cost burden for patients treated with palbociclib. Methods:A retrospective review of patients newly initiated on palbociclib therapy between May 5, 2018 and May 30, 2019 was completed at our institution. Patients were included if they were 18 years of age and older, newly starting palbociclib for advanced or metastatic HR+/HER2- breast cancer, had US-based insurance, and received palbociclib from our internal specialty pharmacy. Cost information was collected utilizing dispensing reports and additional patient-specific information was obtained from the EHR. Descriptive statistics were performed on the collected data. Results:A total of 44 patients were included in the cost analysis. Primary sources of coverage for these patients included commercial insurance (n=13), Medicare (n=25), and state/federal insurance (n=6). We first assessed costs with primary insurance coverage alone. The sum of all the initial cycle out-of-pocket copays after primary insurance totaled $49,108. The median individual copay was $291, the range was $0 to $2,943, and 9 of the 44 patients had no copay after the primary insurance was applied. The impact of assistance programs, which include independent grant funding, copay cards, vouchers, and secondary Medicaid plans, was significant. After applying primary insurance and aid from assistance programs, the sum of all initial cycle out-of-pocket copays reduced from $49,108 to $3,172. After assistance, 33 of the 44 patients had an initial copay cost of $0. Over 90% of the out-of-pocket total was from two patients (one each with a copay of $2,467 and $497). Ultimately, Mayo Clinic Specialty Pharmacy helped patients avoid $45,851 in first cycle out-of-pocket copays, of which $41,079 and $4,772 were for Medicare and commercially-insured patients, respectively. Copay cost by type of insurance was assessed. All patients with commercial insurance (n=13) had no actual copay for the first cycle. Medicare patients (n=25) are not eligible for copay cards and had larger pre-assistance copays compared to commercial patients (median $2,454 vs. $45). Vouchers or grants were utilized by 16 out of 25 Medicare covered patients. State/Federal insurance included 2 Tricare and 4 Medicaid patients. While ineligible for copay card assistance, the copays for these patients were low, ranging from $0-$28. Standard Medicare D plans do not have an out of pocket maximum for the year. The catastrophic phase requires an ongoing copay of 5% of the total claim cost, resulting in approximately a $600 per month copay for the remainder of the calendar year during the study period. When combined with the first cycle cost of approximately $2500, the yearly out-of-pocket cost for a patient with a standard Medicare D plan is roughly $10,000. Conclusion:Patients initiating therapy with palbociclib are commonly faced with high out-of-pocket costs. The availability, eligibility, and use of financial assistance programs are imperative in decreasing the financial toxicity. Specialty pharmacies play an important role in obtaining financial assistance which leads to decreased out-of-pocket expenses for patients. Citation Format: Allison P Golbach, Matthew D Smith, Jodi L Taraba, Karthik V Giridhar. Assessment of patient out-of-pocket cost for palbociclib therapy in advanced breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-49.
Sex-Specific Associations Between Preoperative Anemia and Postoperative Clinical Outcomes in Patients Undergoing Cardiac Surgery
Ripoll, Juan G. , Hanson, Andrew C. , Schulte, Phillip J. , Portner, Erica , Kor, Daryl J. , Smith, Mark M. , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | February 13, 2021 | Volume: 132 | Issue: 4 | Pages: 1101-1111

10.1213/ane.0000000000005392 | PMID 33543869 Get It

BACKGROUND: Preoperative anemia is common in cardiac surgery, yet there were limited data describing the role of sex in the associations between anemia and clinical outcomes. Understanding these relationships may guide preoperative optimization efforts. METHODS: This is an observational cohort study of adults undergoing isolated coronary artery bypass grafting or single- or double-valve surgery from 2008 to 2018 at a large tertiary medical center. Multivariable regression assessed the associations between preoperative hemoglobin concentrations and a primary outcome of postoperative acute kidney injury (AKI) and secondary outcomes of perioperative red blood cell (RBC) transfusion, reoperation, vascular complications (ie, stroke, pulmonary embolism, and myocardial infarction), and hospital length of stay (LOS). Each outcome was a single regression model, using interaction terms to assess sex-specific associations between hemoglobin and outcome. RESULTS: A total of 4117 patients were included (57% men). Linear splines with sex-specific knots (13 g/dL in women and 14 g/dL in men) provided the best overall fit for preoperative hemoglobin and outcome relationships. In women, each 1 g/dL decrease in hemoglobin <13 g/dL was associated with increased odds of AKI (odds ratio = 1.49; 95% confidence interval [CI], [1.23-1.81]; P < .001), and there was no significant association between hemoglobin per 1 g/dL >13 g/dL and AKI (0.90 [0.56-1.45]; P = .67). The association between hemoglobin and AKI in men did not meet statistical significance (1.10 [0.99-1.22]; P = .076, per 1 g/dL decrease <14 g/dL; 1.00 [0.79-1.26]; P = .98 for hemoglobin per 1 g/dL >14 g/dL). In women, lower preoperative hemoglobin (per 1 g/dL decrease <13 g/dL) was associated with increased odds of RBC transfusion (2.90 [2.33-3.60]; P < .001), reoperation (1.27 [1.11-1.45]; P < .001) and a longer hospital LOS (multiplicative increase in geometric mean 1.05 [1.03-1.07]; P < .001). In men, preoperative hemoglobin (per 1 g/dL decrease <14 g/dL) was associated with increased odds of perioperative RBCs (2.56 [2.27-2.88]; P < .001) and longer hospital LOS (multiplicative increase in geometric mean 1.02 [1.01-1.04] days; P < .001) but not reoperation (0.94 [0.85-1.04]; P = .256). Preoperative hemoglobin per 1 g/dL >13 g/dL in women and 14 g/dL in men were associated with lower odds of RBCs transfusion (0.57 [0.47-0.69]; P < .001 and 0.74 [0.60-0.91]; P = .005, respectively). CONCLUSIONS: Preoperative anemia was associated with inferior clinical outcomes after cardiac surgery. The associations between hemoglobin and outcomes were distinct for women and men, with different spline knot points identified (13 and 14 g/dL, respectively). Clinicians should consider data-driven approaches to determine preoperative hemoglobin values associated with increasing risk for adverse perioperative outcomes across sexes.
Physician variation in the de‐adoption of ineffective statin and fibrate therapy
Everhart, Alexander , Dowd, Bryan , Herrin, Jeph , Higuera, Lucas , Jeffery, Molly M. , Jena, Anupam B. , Shah, Nilay D., Smith, Laura Barrie , Karaca‐Mandic, Pinar , Dowd, Bryan , Herrin, Jeph , Jeffery, Molly Moore , Jena, Anupam B , Karaca-Mandic, Pinar , Everhart, Alexander O , Desai, Nihar R. , Ross, Joseph S.

Mayo Clinic

Health Services Research | February 11, 2021 | Volume: 56 | Issue: 5 | Pages: 919-931

10.1111/1475-6773.13630 | PMID 33569804 Get It

AbstractObjectiveTo describe physicians’ variation in de‐adopting concurrent statin and fibrate therapy for type 2 diabetic patients following a reversal in clinical evidence.Data SourcesWe analyzed 2007‐2015 claims data from OptumLabs® Data Warehouse, a longitudinal, real‐world data asset with de‐identified administrative claims and electronic health record data.Study DesignWe modeled fibrate use among Medicare Advantage and commercially insured type 2 diabetic statin users before and after the publication of the ACCORD lipid trial, which found statins and fibrates were no more effective than statins alone in reducing cardiovascular events among type 2 diabetic patients. We modeled fibrate use trends with physician random effects and physician characteristics such as age and specialty.Data ExtractionWe identified patient‐year‐quarters with one year of continuous insurance enrollment, type 2 diabetes diagnoses, and fibrate use. We designated the physician most responsible for patients’ diabetes care based on evaluation and management visits and prescriptions of glucose‐lowering drugs.Principal FindingsFibrate use increased by 0.12 percentage points per quarter among commercial patients (95% CI, 0.10 to 0.14) and 0.17 percentage points per quarter among Medicare Advantage patients (95% CI, 0.13 to 0.20) before the trial and then decreased by 0.16 percentage points per quarter among commercial patients (95% CI, −0.18 to −0.15) and 0.05 percentage points per quarter among Medicare Advantage patients (95% CI, −0.06 to −0.03) after the trial. However, 45% of physicians treating commercial patients and 48% of physicians treating Medicare Advantage patients had positive trends in prescribing following the trial. Physicians’ characteristics did not explain their variation (pseudo R2 = 0.000).ConclusionOn average, physicians decreased fibrate prescribing following the ACCORD lipid trial. However, many physicians increased prescribing following the trial. Observable physician characteristics did not explain variations in prescribing. Future research should examine whether physicians vary similarly in other de‐adoption settings.
Temperature‐corrected proton density fat fraction estimation using chemical shift‐encoded MRI in phantoms
Navaratna, Ruvini , Zhao, Ruiyang , Colgan, Timothy J. , Hu, Peng , Bydder, Mark , Bashir, Mustafa R. , Middleton, Michael S. , Serai, Suraj D. , Chenevert, Thomas L. , Smith, Mark A. , Henderson, Walter C. , Hamilton, Gavin , Shu, Yunhong , Tkach, Jean A. , Brittain, Jean H. , Hu, Houchun Harry , Serai, Suraj D , Shu, Yunhong , Trout, Andrew T , Hernando, Diego , Reeder, Scott B. , Hamilton, Gavin , Yokoo, Takeshi , Malyarenko, Dariya I. , Sirlin, Claude B. , Trout, Andrew T.

Mayo Clinic

Magnetic Resonance in Medicine | February 11, 2021 | Volume: 86 | Issue: 1 | Pages: 69-81

10.1002/mrm.28669 | PMID 33565112 Get It

PurposeChemical shift‐encoded MRI (CSE‐MRI) is well‐established to quantify proton density fat fraction (PDFF) as a quantitative biomarker of hepatic steatosis. However, temperature is known to bias PDFF estimation in phantom studies. In this study, strategies were developed and evaluated to correct for the effects of temperature on PDFF estimation through simulations, temperature‐controlled experiments, and a multi‐center, multi‐vendor phantom study.Theory and MethodsA technical solution that assumes and automatically estimates a uniform, global temperature throughout the phantom is proposed. Computer simulations modeled the effect of temperature on PDFF estimation using magnitude‐, complex‐, and hybrid‐based CSE‐MRI methods. Phantom experiments were performed to assess the temperature correction on PDFF estimation at controlled phantom temperatures. To assess the temperature correction method on a larger scale, the proposed method was applied to data acquired as part of a nine‐site multi‐vendor phantom study and compared to temperature‐corrected PDFF estimation using an a priori guess for ambient room temperature.ResultsSimulations and temperature‐controlled experiments show that as temperature deviates further from the assumed temperature, PDFF bias increases. Using the proposed correction method and a reasonable a priori guess for ambient temperature, PDFF bias and variability were reduced using magnitude‐based CSE‐MRI, across MRI systems, field strengths, protocols, and varying phantom temperature. Complex and hybrid methods showed little PDFF bias and variability both before and after correction.ConclusionCorrection for temperature reduces temperature‐related PDFF bias and variability in phantoms across MRI vendors, sites, field strengths, and protocols for magnitude‐based CSE‐MRI, even without a priori information about the temperature.
Detection of bacterial fluorescence from in vivo wound biofilms using a point‐of‐care fluorescence imaging device
Jones, Laura , Reynolds, Landrye, Diaz, Rachel C., George, Isaiah K., Little, William, Fleming, Derek , D’souza, Anna, Rumbaugh, Kendra P. , Smith, Allie Clinton , Fleming, Derek , López, Andrea J. , Rennie, Monique Y.

Mayo Clinic

International Wound Journal | February 11, 2021 | Volume: 18 | Issue: 5 | Pages: 626-638

10.1111/iwj.13564 | PMID 33565263 Get It

AbstractWound biofilms must be identified to target disruption and bacterial eradication but are challenging to detect with standard clinical assessment. This study tested whether bacterial fluorescence imaging could detect porphyrin‐producing bacteria within a biofilm using well‐established in vivo models. Mouse wounds were inoculated on Day 0 with planktonic bacteria (n = 39, porphyrin‐producing and non‐porphyrin‐producing species, 107 colony forming units (CFU)/wound) or with polymicrobial biofilms (n = 16, 3 biofilms per mouse, each with 1:1:1 parts Staphylococcus aureus/Escherichia coli/Enterobacter cloacae, 107 CFU/biofilm) that were grown in vitro. Mouse wounds inoculated with biofilm underwent fluorescence imaging up to Day 4 or 5. Wounds were then excised and sent for microbiological analysis. Bacteria‐matrix interaction was assessed with scanning electron microscopy (SEM) and histopathology. A total of 48 hours after inoculation with planktonic bacteria or biofilm, red fluorescence was readily detected in wounds; red fluorescence intensified up to Day 4. Red fluorescence from biofilms persisted in excised wound tissue post‐wash. SEM and histopathology confirmed bacteria‐matrix interaction. This pre‐clinical study is the first to demonstrate the fluorescence detection of bacterial biofilm in vivo using a point‐of‐care wound imaging device. These findings have implications for clinicians targeting biofilm and may facilitate improved visualisation and removal of biofilms.
Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show?
Candow, Darren G. , Kreider, Richard B. , Rawson, Eric S., VanDusseldorp, Trisha A. , Willoughby, Darryn S. , Ziegenfuss, Tim N. , Antonio, Jose , Kreider, Richard B , António, José , Forbes, Scott C. , Gualano, Bruno , Jagim, Andrew R. , Smith‐Ryan, Abbie E.

Mayo Clinic

Journal of the International Society of Sports Nutrition | February 8, 2021 | Volume: 18 | Issue: 1 | Pages: No page available

10.1186/s12970-021-00412-w | PMID 33557850 Get It

A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015
Smith, Caleb J. , Ruan, Gordon , Thomas, John W., Tefferi, Ayalew , Goyal, Guarav, Go, Ronald S. , Shah, Meera

Mayo Clinic

Blood | February 8, 2021 | Volume: 136 | Issue: Supplement 1 | Pages: 48-48

10.1182/blood-2020-137611 Get It

Introduction: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF) are BCR/ABL1-negative myeloproliferative neoplasms (MPN) that are associated with morbidity and increased mortality. Limited data regarding population-based outcomes for these MPNs have been reported. Our aim was to use the Surveillance, Epidemiology, and End Results (SEER) registry to investigate population based outcomes for PV, ET, and PMF. Methods: The SEER 18 registries were used to identify patients with ICD-O-3 diagnosis codes for PV (9950/3), ET (9962/3), and PMF (9961/3) from 2001-2015. For ET and PMF, histologic diagnosis was required for inclusion. Incidence was age-adjusted to the U.S. 2000 standard population. Causes of death were obtained and MPN-related death was defined as death from any myeloid disorder (ET, PV, PMF, acute myeloid leukemia [AML], acute monocytic leukemia, other myeloid/monocytic leukemia, and aleukemic, subleukemic and NOS). Relative survival (RS) was defined as the ratio of the proportion of observed survivors in a cohort of PV, ET, PMF patients to the proportion of expected survivors in a comparable set of individuals that did not respectively have PV, ET, or PMF, adjusting for the general survival of the US population for race, sex, age, and time when the diagnosis was established. Time to leukemic transformation was calculated using the left-truncated life tables session with a 3-month latency period used to prevent misattribution. Overall survival (OS) was calculated between the date of diagnosis and the date of death, date last known to be alive, or date of the study cut-off (31 December 2018). Variables significant in univariate analysis were included in a multivariate analysis. The Kaplan-Meier method was used to calculate overall survival (OS), and Cox regression model was used to identify predictors of survival. Statistical analyses were performed using JMP version 14.0. Results: 10,988 patients with PV, 9,146 with ET, and 4,022 with PMF were identified in SEER. The median age of diagnosis (interquartile range [IQR]) was 65 years (IQR 54-76), 67 years (IQR 54-77), and 69 years (IQR 60-78) for PV, ET, and PMF respectively. Overall incidence rates (cases/100,000) were 0.86 for PV, 0.72 for ET, and 0.30 for PMF. With a median follow up (in years, 95% confidence interval [CI]) of 7.6 (7.4-7.8), 7.9 (7.8-8.2), and 7.25 (7.0-7.5), the median OS was 11.4 (11.2-11.7), 11.75 (11.3-12.0), and 3.5 (3.3-3.7), for PV, ET, and PMF respectively. RS was better than expected survival for PV and ET, while less than expected survival for PMF (Figure 1). 3853 of PV patients died (35.1%) by the end of the study period, with 4.1% and 34.1% of deaths from PV-related and cardiovascular disease respectively (Table 1). 3142 of ET patients died (34.4%), with 7.2% and 32.2% of deaths from ET-related and cardiovascular disease respectively. 2578 patients with MF died (64.1%), with 13.2%, and 51.9% of deaths from PMF-related and other malignancies respectively. 106 patients (1.0%) with PV, 135 patients (1.5%) with ET, and 127 patients (3.2%) with PMF transformed to AML. Median time to transformation was 4.8, 6.3, and 2.3 years for PV, ET, and PMF respectively. Factors indicating inferior OS on multivariate analysis (Table 2) included age ≥ 65, female sex, and year of diagnosis for PV, age ≥ 65, male sex, and year of diagnosis for ET, and age ≥ 65, and male sex for PMF. Conclusion: Incidence rates for PV, ET, and PMF were similar to previous reports. RS was better than expected survival for PV and ET, while less than expected survival for PMF. The majority of deaths in ET and PV occurred from cardiovascular disease; a finding likely related to these MPNs. Patients with PMF were more likely to die from their disease or a subsequent malignancy. Transformation to AML occurred less frequently than prior large case series, noting a limitation in the current study. Patients with PMF were more likely to transform to AML with a shorter time interval. Older age was associated with worse OS in all patients. Male sex was predictive of worse survival for ET and PMF, while female sex was associated with worse survival in PV. Over the years, survival has improved for PV and remained essentially unchanged for ET and PMF. Figure Disclosures Shah: Dren Bio: Consultancy.
Identification and characterization of the antigen recognized by the germ cell mAb TRA98 using a human comprehensive wet protein array
Fukuda, Eriko , Tanaka, Hiromitsu , Yamaguchi, Kei, Takasaka, Mieko, Kawamura, Yoshifumi , Isotani, Ayako , Tsuchida, Junji, Okada, Yuki , Tsujimura, Akira , Miyagawa, Yasushi, Fukuhara, Shinichiro , Kawakami, Y., Wada, Morimasa, Nishimune, Yoshitake, Goshima, Naoki , Shapiro, Virginia Smith , Okuda, Hidenobu, Ikawa, Masahito

Mayo Clinic

Genes to Cells | February 3, 2021 | Volume: 26 | Issue: 3 | Pages: 180-189

10.1111/gtc.12832 | PMID 33527666 Get It

AbstractTRA98 is a rat monoclonal antibody (mAb) which recognizes a specific antigen in the nuclei of germ cells. mAb TRA98 has been used to understand the mechanism of germ cell development and differentiation in many studies. In mice, the antigen recognized by mAb TRA98 or GCNA1 has been reported to be a GCNA gene product, but despite the demonstration of the immunoreactivity of this mAb in human testis and sperm in 1997, the antigen in humans remains unknown, as of date. To identify the human antigen recognized by mAb TRA98, a human comprehensive wet protein array was developed containing 19,446 proteins derived from human cDNAs. Using this array, it was found that the antigen of mAb TRA98 is not a GCNA gene product, but nuclear factor‐κB activating protein (NKAP). In mice, mAb TRA98 recognized both the GCNA gene product and NKAP. Furthermore, conditional knockout of Nkap in mice revealed a phenotype of Sertoli cell‐only syndrome. Although NKAP is a ubiquitously expressed protein, NKAP recognized by mAb TRA98 in mouse testis was SUMOylated. These results suggest that NKAP undergoes modifications, such as SUMOylation in the testis, and plays an important role in spermatogenesis.
Rurality, Death, and Healthcare Utilization in Heart Failure in the Community
Manemann, Sheila M., Henning‐Smith, Carrie , Rutten, Lila J. Finney , Chamberlain, Alanna M. , Fabbri, Matteo, Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , St Sauver, Jennifer, Finney Rutten, Lila J , Chamberlain, Alanna M , Sauver, Jennifer L. St.

Mayo Clinic

Journal of the American Heart Association | February 3, 2021 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/jaha.120.018026 | PMID 33533260 Get It

Background Prior reports indicate that living in a rural area may be associated with worse health outcomes. However, data on rurality and heart failure (HF) outcomes are scarce. Methods and Results Residents from 6 southeastern Minnesota counties with a first‐ever code for HF ( International Classification of Diseases, Ninth Revision [ ICD‐9 ], code 428, and International Classification of Diseases, Tenth Revision [ ICD‐10 ] code I50) between January 1, 2013 and December 31, 2016, were identified. Resident address was classified according to the rural‐urban commuting area codes. Rurality was defined as living in a nonmetropolitan area. Cox regression was used to analyze the association between living in a rural versus urban area and death; Andersen‐Gill models were used for hospitalization and emergency department visits. Among 6003 patients with HF (mean age 74 years, 48% women), 43% lived in a rural area. Rural patients were older and had a lower educational attainment and less comorbidity compared with patients living in urban areas ( P <0.001). After a mean (SD) follow‐up of 2.8 (1.7) years, 2440 deaths, 20 506 emergency department visits, and 11 311 hospitalizations occurred. After adjustment, rurality was independently associated with an increased risk of death (hazard ratio [HR], 1.18; 95% CI, 1.09–1.29) and a reduced risk of emergency department visits (HR, 0.89; 95% CI, 0.82–0.97) and hospitalizations (HR, 0.78; 95% CI, 0.73–0.84). Conclusions Among patients with HF, living in a rural area is associated with an increased risk of death and fewer emergency department visits and hospitalizations. Further study to identify and address the mechanisms through which rural residence influences mortality and healthcare utilization in HF is needed in order to reduce disparities in rural health.